Journal
AIDS
Volume 25, Issue 2, Pages 153-158Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e328342115c
Keywords
acquisition risk; adenovirus; HIV; MSM; serology; vaccine
Categories
Funding
- National Institute of Allergy and Infectious Diseases, National Institutes of Health [U01 AI052054, AI30731]
- National Institute of Allergy and Infectious Diseases [U01 AI46749]
- National Institute of Child Health and Human Development
- National Institute of Drug Abuse
- National Institute of Mental Health, and Office of AIDS Research
- National Institute of Allergy and Infectious Diseases
- National Cancer Institute
- National Heart, Lung and Blood Institute
- GlaxoSmithKline
- [UO1-AI-35042]
- [5-MO1-RR-00722 (GCRC)]
- [UO1-AI-35043]
- [UO1-AI-37984]
- [UO1-AI-35039]
- [UO1-AI-35040]
- [UO1-AI-37613]
- [UO1-AI-35041]
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI037613, U01AI035041, U01AI035042, U01AI037984, U01AI035040, U01AI046749, P01AI030731, U01AI035043, U01AI035039, R01AI052054, U01AI052054] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background: Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. Methods: We performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. Results: In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. Conclusion: The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available